New-onset heart failure in the STOP-HF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure (vol 22, pg 378, 2020)

被引：0
|
作者：
McClelland, S.
Zhou, S.
O'Connell, E.
Gallagher, J.
Ryan, F.
Watson, C. J.
Ledwidge, M.
McDonald, K.
机构：
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2020年 / 22卷 / 06期
关键词：
D O I：
10.1002/ejhf.1930
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1056 / 1056
页数：1
相关论文
共 14 条
  • [1] New-onset heart failure in the STOP-HF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure
    McClelland, Sarah
    Zhou, Shuaiwei
    O'Connell, Eoin
    Gallagher, Joseph
    Ryan, Fiona
    Watson, Chris J.
    Ledwidge, Mark
    McDonald, Kenneth
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (02) : 378 - 380
  • [2] BASELINE B-TYPE NATRIURETIC PEPTIDE IS THE STRONGEST PREDICTOR OF TRANSITION TO STAGE C HEART FAILURE IN AN AT-RISK POPULATION; RESULTS FROM THE STOP-HF PREVENTION PROGRAMME
    Mc Cleland, S.
    Zhou, S.
    O'Connell, E.
    Ledwidge, M.
    Murphy, R.
    Watson, C.
    Healy, L.
    Ryan, F.
    Gallagher, J.
    McDonald, K.
    [J]. HEART, 2018, 104 : A3 - A4
  • [3] Baseline B-type natriuretic peptide is the strongest predictor of transition to stage C heart failure in an at-risk population; Results from the STOP-HF prevention programme
    McClelland, S.
    Healy, L.
    Murphy, R.
    Zhou, S.
    Gallagher, J.
    Watson, C.
    Ledwidge, M.
    McDonald, K.
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 : 1198 - 1198
  • [4] Baseline B-type natriuretic peptide is the strongest predictor of transition to stage C heart failure in an at-risk population; Results from the STOP-HF prevention programme
    Mcclelland, S.
    Healy, L.
    Murphy, R.
    Zhou, S.
    Gallagher, J.
    Watson, C.
    Ledwidge, M.
    Mcdonald, K.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 13 - 13
  • [5] Left Ventricular Ejection Fraction Assessment in Older Adults An Adjunct to Natriuretic Peptide Testing to Identify Risk of New-Onset Heart Failure and Cardiovascular Death?
    deFilippi, Christopher R.
    Christenson, Robert H.
    Kop, Willem J.
    Gottdiener, John S.
    Zhan, Min
    Seliger, Stephen L.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (14) : 1497 - 1506
  • [6] Left ventricular ejection fraction assessment in older adults an adjunct to natriuretic peptide testing to identify risk of new-onset heart failure and cardiovascular death
    [J]. South China Journal of Cardiology, 2011, (03) : 205 - 205
  • [7] B-type natriuretic peptide independently predicts all-cause mortality and new-onset congestive heart failure in a high-risk, asymptomatic population: The strong heart study
    Krauser, D
    Rodeheffer, RJ
    Burnett, JC
    Kizer, JR
    Howard, BV
    Best, LG
    Lee, ET
    Devereux, RB
    [J]. CIRCULATION, 2005, 112 (17) : U867 - U868
  • [8] ASSESSING THE LONG-TERM COST-EFFECTIVENESS OF NATRIURETIC PEPTIDE-BASED SCREENING AND COLLABORATIVE CARE IN AT RISK POPULATION: ANALYSIS FROM THE STOP-HF (ST VINCENT'S SCREENING TO PREVENT HEART FAILURE) STUDY
    Murphy, T.
    Ledwidge, M.
    Hopkins, G.
    McDonald, K.
    [J]. HEART, 2018, 104 : A23 - A24
  • [9] Usefulness of 13-type natriuretic peptide (BNP) for the diagnosis of new-onset heart failure with a preserved left ventricular systolic function in longstanding hypertensive patients with acute dyspnea
    Arques, S.
    Roux, E.
    Sbragia, P.
    Pieri, B.
    Gelisse, R.
    Luccioni, R.
    Ambrosi, P.
    [J]. ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 2007, 100 (02): : 113 - 120
  • [10] B-type natriuretic peptide measurement in primary care; magnitude of associations with cardiovascular risk factors and their therapies. Observations from the STOP-HF (St. Vincent's Screening TO Prevent Heart Failure) study
    Conlon, Carmel M.
    Dawkins, Ian
    O'Loughlin, Christina
    Gibson, Denise
    Kelleher, Cecily C.
    Ledwidge, Mark
    McDonald, Kenneth
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (04) : 719 - 728
12